Slide 1: Fiscal 2025 3Q Financial Results
Fiscal 2025 3Q Financial Results AU GU ST 2 0 2 5
Slide 2: Agenda
Agenda Welcome Angela Bitting SVP, Corporate Affairs Quarterly Highlights Emily Leproust Chief Executive Officer Business Highlights Patrick Finn President and Chief Operating Officer Financial and Operational Performance Adam Laponis Chief Financial Officer Milestones Emily Leproust Chief Executive
Slide 3: Legal Disclaimers
Legal Disclaimers This presentation contains forward-looking statements. All statements other than statements of historical facts contained herein are forward- looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private
Slide 4: Financial Results
Financial Results
Slide 5: Highlights from the Quarter
Highlights from the Quarter $(8.0)M Adj $96.1M Revenue 53.4% Gross Margin EBITDA* Met guidance of Achieved >50%+ Beat guidance ~$94-97M by 4QFY25 of $(13)M *Adjusted EBITDA is defined as net in come (loss) adjuste d to exclu de inte rest income, intere st exp ense, income ta x expense, d epreciation
Slide 6: 3Q FY25 Next Up Innovative Products (SynBio)
1 SynBio Write 3Q FY25 NEXT UP • $35.2 million in revenue ✓ Wilsonville, OR ✓ Enzyme engineering manufacturing launch • Growth of 7% YoY • RNA ✓ Express Genes • Shipped approximately 237,000 genes • GMP ✓ Additional Express • Expanded Express turnaround time for all Gene products Fragments ✓ 500bp o
Slide 7: 3Q FY25 Next Up Innovative Products (NGS)
2 NGS Read 3Q FY25 NEXT UP ✓ RNA sequencing workflow ✓ SNP microarray • $55.3 million in revenue conversion (ongoing) ✓ Liquid biopsy (ongoing) • Growth of 27% YoY ✓ Enzyme-improved ✓ MRD growth (ongoing) • Expanded collaboration with Element workflows (ongoing) Biosciences ✓ Regulated products ✓ Ad
Slide 8: 3Q FY25 Next Up One-Stop-Shop Biopharma Solutions
3 Biopharma Solutions 3Q FY25 NEXT UP • $5.6 million in revenue ✓ Integrated offering • Growth of 10% YoY ✓ Human clinical studies initiated using antibody discovered through Twist Biopharma Solutions • $6.2 million in orders • Scaling orders • Launched humanized transgenic mouse model • Scaling rev
Slide 9: Combined Biopharma Business
3 Biopharma Solutions Combined Biopharma Business 111 88 Active Programs Programs Started Broad Disease Indications Cancer, Neurology, 430 Immuno-oncology, Partners Infectious Disease, Canine / Feline, Other 1,133 82 Varied Completed Milestones/ Modalities Programs Royalties mAbs, Bispecific Antibod
Slide 10: Crossing the Threshold to Profitability
Crossing the Threshold to Profitability Continued revenue and margin growth Strong operational and commercial execution Platform enhancements and new products Adjusted EBITDA Breakeven Market and wallet share expansion Growing markets 10 | TWIST BIOSCIENCE | PROPRIETARY
Slide 11: Strong Quarterly Revenue Growth
Strong Quarterly Revenue Growth $ in Millions Biopharma $96.1 NGS $92.8 $88.7 SynBio $84.7 $81.5 $75.3 $71.5 $66.9 $63.7 $60.2 $56.1 $57.3 $54.2 $48.1 $42.0 $38.0 $35.0 $32.4 $31.2 $28.2 $21.2 $19.3 $15.7 $17.2 $13.6 $13.6 $11.5 Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar
Slide 12: Revenue by Geography
Revenue by Geography $ in Millions Americas EMEA APAC Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025 12 | TWIST BIOSCIENCE | PROPRIETARY
Slide 13: Adjusted EBITDA Progress Toward Break-even
Adjusted EBITDA Progress Toward Break-even $ Millions $92.8 $96.1 $88.7 $81.5 $84.7 $75.3 53.4% $71.5 GM $63.7 $66.9 49.6% 48.3% GM 45.1% GM 43.3% GM 41.0% GM 40.5% GM GM 36.6% 34.4% GM GM FY23Q3 FY23Q4 FY24Q1 FY24Q2 FY24Q3 FY24Q4 FY25Q1 FY25Q2 FY25Q3 Adj. SG&A + Adj. R&D* $58.3M $57.4M $63.3M $64.4
Slide 14: Additional Financial Commentary
Additional Financial Commentary Q3 FY2025 Revenue $96.1M Gross Margin 53.4% R&D Expenses $18.0M SG&A Expenses $63.4M Gain from Sale of Business $48.8M Net Income / (Loss) Attributable $20.4M to Common Stockholders Adjusted EBITDA* ($8.0M) Cash, Cash Equivalents and Short-term Investments as of June
Slide 15: FY2025 Guidance
From quarterly update - to discuss with AB FY2025 Guidance Q4 FY2025 FY2025 Guidance* Guidance* ~$96 to $98M ~$374 to $376M ~$38 to 39M SynBio Revenue ~$52 to 53M NGS ~$144 to 145M SynBio ~$207 to 208M NGS ~$6M Biopharma ~$23M Biopharma GM 51 to 52% 50.5 to 51% Adjusted EBITDA** ~$(6 to 8M) ~$(45 to
Slide 16: Continued Product Innovation
Continued Product Innovation 1 2 3 SynBio NGS Biopharma Write Read Solutions ✓ Long Gene Fragments ✓ Tumor Informed MRD ✓ AI/ML Affinity Maturation ✓ Multiplexed Gene Fragments ✓ IVDR Exome ✓ Yeast Display for Antibody ✓ ISO13485 DNA Prep ✓ Ultra High Throughput Optimization (TAO) ✓ IgG CHO FlexPrep
Slide 17: Our Next Chapter
Our Next Chapter Continued revenue and margin growth Strong operational and commercial execution Platform enhancements and new products Market and wallet share expansion Growing markets Market Understanding Culture of Innovation Proven Technology Strong Differentiation Scalable Infrastructure Commer
Slide 18: Writing the Future
Writing the Future
Slide 19: Additional Slides
Additional Slides
Slide 20: Adjusted EBITDA Reconciliation
Adjusted EBITDA Reconciliation (In Thousands) Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 GAAP Net Income $(57,395) $(46,243) $(43,008) $(45,492) (85,571) $(34,655) $(31,594) $(39,328) 20,390 Add (Deduct) Adjustments: Interest Income (3,968) (3,893) (4,120) (3,941) (3,663
Slide 21: Adjusted R&D and SG&A Expenses Reconciliation
Adjusted R&D and SG&A Expenses Reconciliation (In Millions) Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 R&D Expenses — GAAP $24.5 $23.7 $23.1 $24.1 $22.5 $21.1 $21.3 $23.9 $18.0 Adjusted to exclude: Depreciation and Amortization 1.2 0.8 0.9 0.9 0.9 0.5 0.4 0.4 0.2 Stock-b